Why AI Can't Help Bad ClinOps/Health Equity Data, Panavance's IND Prep Ahead Of FDA Submission For Ovarian Cancer Trial, and More
Clinical Leader
A resource and forum to investigate and resolve the common struggles related to running effective clinical trials.
Welcome to the Clinical Trial Insights newsletter, featuring strategic insights and expert opinions on designing and running clinical trials. Each edition covers the latest trending articles on ClinicalLeader.com.
In this week's issue, we'll review the opportunity to connect disparate ClinOps data and leverage generative AI to reduce costs and labor, how the FDA's latest diversity draft guidance substantiates the mandate of a Diversity Action Plan for late-stage trial protocol submissions, Panavance's pursuit of a second trial for misetionamide, how to avoid CRO turnover, and other popular insights.
If you like what you're seeing in our condensed LinkedIn editions, subscribe to our daily newsletter for full access to exclusive articles, webinars, e-books, and more! Subscribe Now →
WEBINAR 12.10.24
What’s Wrong with My Trial? Uncovering the Cause of Clinical Trial Troubles
Join us for a webinar discussion with inSeption Group on 12/10, where we'll explore the most critical steps companies can take to prevent trials from reaching a point of crisis and the importance of addressing systemic issues before they escalate.
TOP 5 READS OF THE PAST WEEK
Brian H. Johnson,Ph.D. , VP, R&D Technology at Takeda discusses the huge opportunity of connecting disparate ClinOps data and leveraging generative AI to reduce costs and labor during the clinical process.
The highly anticipated draft guideline, Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials as part of the Federal Drug and Omnibus Reform Act (FDORA), was recently released. Explore how it substantiates the mandate of a Diversity Action Plan (DAP) for late-stage trial protocol submissions.
In this interview, Panavance Therapeutics Inc. CEO Greg Bosch discusses the company’s pursuit of a second trial for misetionamide, walking us through IND preparations, CRO selection, and securing funding.
According to the CRO Industry Global Compensation & Turnover Survey, the average total turnover for U.S. clinical monitoring roles as of 2022 was 26%. Though some turnover is an inevitable part of a business’s life cycle, there are several strategies available to ensure a consistent CRO team throughout the span of your trial.
In the final article of this series, Liam Eves and Kym Denny Eves explore how various drug candidates come inherent with barriers to adoption that directly impact how participants and providers engage with clinical research.
MORE TO EXPLORE
Clinical Leader is an online community serving professionals in the clinical research space. We share insights and best practices — from industry experts — to help sponsors and CROs tackle the biggest challenges they face in designing and running clinical trials.
To get the most out of our offerings, join the Clinical Leader community.